Table 5.
Randomized control trials using aspirin for preeclampsia prevention that included women with chronic hypertension.
| Included in USPSTF Review | Author | ASA Dosage (mg daily) | Preeclampsi a in ASA group | Preeclampsi a in Placebo group | OR | P value | % of patients with CHTN | Incidenc e of Preeclam psia in CHTN patients | GA at ASA initiation (weeks) |
|---|---|---|---|---|---|---|---|---|---|
| Yes | Viinikka 199330 | 50 | 9/97 | 11/100 | 0.83 (0.33 – 2.10) | 0.82 | 83% | No data | 15–16 |
| Yes | CLASP 199426 | 60 | 257/3449 | 290/3437 | 0.87 (0.73 – 1.04) | 0.14 | 20% | No data | 12 – 32 |
| Yes | MFMU 199825 | 60 | 229/1273 | 253/1266 | 0.88 (0.72 – 1.07) | 0.21 | 30% | 26% ASA vs 25% placebo (p = 0.66) | 13–26 |
| Yes | Ayala 201327 | 100 | 11/176 | 22/174 | 0.49 (0.25–0.99) | N/A | No data | 12–16 | |
| Yes | Grab 200028 | 100 | 3/22 | 2/21 | 1.50 (0.23 – 10.02) | 1.00 | 44% | No data | 18 |
| Yes | Hermida 199729 | 100 | 3/50 | 7/50 | 0.43 (0.12–1.56) | N/A | No data | 12–16 | |
| Yes | Villa 201231 | 100 | 8/61 | 11/60 | 0.67 (0.25 – 1.81) | 0.46 | 17% | No data | 12–13 |
| No | ECPPA 199632 | 60 | 32/496 | 30/494 | 1.07 (0.64 – 1.78) | 0.90 | 47% | No data | 12–32 |
| No | Byaruhanga 199833 | 75 | 17/113 | 23/117 | 0.72 (0.36 – 1.44) | 0.39 | 16% | No data | 20–28 |
| No | Vainio 200234 | 86 | 2/43 | 10/43 | 0.2 (0.05–0.86) | 34% | No data | 12–14 | |
| No | Ebrashy 200535 | 75 | 26/74 | 40/65 | - | - | 35% | No data | 14–16 |
| No | Zhao, 201264 | 75 | 22/120 | 64/122 | - | - | N/A | No data | 13–16 |
| No | Odibo 201536 | 81 | 3/16 | 3/14 | 0.85 (0.14 – 5.07) | 1.00 | 53% | No data | 18–32 |
| No | Stanescu 201565 | 150 | 0/100 | 2/50 | 0.96 (0.91 – 1.02) | 0.11 | N/A | No data | 11–14 |
| No | ASPRE 201737 | 150 | 66/798 | 94/822 | 0.70 (0.50 – 0.97) | 0.04 | 7% | 5/49 ASA vs 5/61 placebo 1.22 (0.33 – 4.49) P = 1.0 | 11–14 |
| Total | 688/6888 | 862/6835 | |||||||
USPSTF: United States Preventative Services Task Force; ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevencao da Pre-eclampsia com Aspirina) Collaborative Group; CHTN: chronic hypertension; MFMU: Maternal Fetal Medicine Units network; ASPRE: Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia; N/A: not available; ASA: aspirin; GA: gestational age; OR: odds ratio.